Replies to post #37443 on Amarin Corp Plc (AMRN)

[HDGabor]

I do not think dilution is coming. And definitely not at this level. A lot of option is available. Just one example: more loan from Pharmakon.

AMRN has to act by end of Q2 / beginning of Q3 2015, if no significant increase in script. Until that a lot of thing could happen to support the pps:

- NCE: I am optimistic based on previous cases (moiety vs ingredient)
- AZN patent case: I am also optimistic, since AZN main argument is - Epanova not on the market. They are not challenging the patent itself (forget that stupid active arm argument)
- CRL: I am not optimistic, but it could be "positive" (ie.: suggest accelerated submission, data on label)